An interventional study of PET-MRI (Positron Emission Tomography - Magnetic Resonance Imaging). in Parkinson's Disease (PD), sponsored by University Hospital, Clermont-Ferrand. Recruiting at 3 sites in France. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-08.
Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Disruptive, Impulse Control, and Conduct Disorders with a site in France — 3 open to participants now, 3 under way, none of them phase 3. Disruptive, Impulse Control, and Conduct Disorders · France.
Among the 12 studies in Disruptive, Impulse Control, and Conduct Disorders with a site in France, this one is one of 2 that started in 2026, is one of 5 with no phase, and was the 11th registered.
56 studies on the registry are indexed under Disruptive, Impulse Control, and Conduct Disorders; 17 are open to participants now.
Browse Disruptive, Impulse Control, and Conduct Disorders studies →3 of the 12 studies in Disruptive, Impulse Control, and Conduct Disorders with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University Hospital, Strasbourg, France · Sites in France
Ages 35–75
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 15 Disruptive, Impulse Control, and Conduct Disorders studies recruiting now, 4 (27%) set no upper age limit and 10 (67%) stop at 75 or younger; none take children under 18; 5 take healthy volunteers.
This study: 45 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 44 is close to the median of 48 across 46 interventional studies indexed under Disruptive, Impulse Control, and Conduct Disorders.
Median enrollment 45 across the 9 interventional studies, 100 across the 3 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 12 has an industry lead sponsor. The 6 most frequent:
University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 177 are open to participants now.
University Hospital, Clermont-Ferrand has 4 studies filed under Disruptive, Impulse Control, and Conduct Disorders — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Disruptive, Impulse Control, and Conduct Disorders with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Impulse control disorders (ICDs) are frequently observed in Parkinson's disease (PD) and can have a major functional impact on the quality of life of both the patient and their entourage. The primary risk factor for the emergence of ICDs in PD is long-term dopaminergic treatment, but other risk factors, such as rapid eye movement sleep behavior disorder (RBD), have recently been identified. The mechanisms leading to ICDs in PD remain debated, but it has been shown that the dopaminergic mesocorticolimbic pathways play a key role in reward, learning, and reinforcement processes, as well as in the regulation of impulsivity. PET studies using [11C]raclopride, a tracer that allows evaluation of the postsynaptic availability of dopamine D2/D3 receptors, have demonstrated abnormal sensitization of the mesocorticolimbic dopaminergic system (the reward system), particularly in the ventral striatum, in Parkinson's patients with ICDs when presented with appetitive stimuli or during gambling tasks. However, this has never been studied in patients with and without RBD. Parkinson's patients with RBD may present greater impairment of mesocorticolimbic pathways than those without RBD, particularly abnormal sensitization and postsynaptic modifications of the dopaminergic system, which could predispose patients to the emergence of ICDs when exposed to dopaminergic agonists. Confirming a particular pattern of denervation in Parkinson's patients with RBD that may favor the emergence of ICDs constitutes a personalized medicine approach with a readily identifiable risk marker in routine clinical practice and offers the possibility of adapting the management of these patients.
The main objective of this study is to investigate the availability of D2 dopaminergic receptors in subcortical structures (particularly the mesocorticolimbic system) in patients with idiopathic Parkinson's disease, depending on the presence or absence of RBD
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with impulse control disorders, defined by either of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: PET-MRI (Positron Emission Tomography - Magnetic Resonance Imaging).
control group
Other: PET-MRI (Positron Emission Tomography - Magnetic Resonance Imaging).
The PET-MRI will be performed using a Siemens Biograph mMR hybrid PET-MRI scanner. A 60-minute dynamic PET acquisition will begin following the intravenous injection of \\\[¹¹C\]raclopride (a radiotracer agonist of dopamine D2/D3 receptors) synthesized in the radiopharmaceutical laboratories of CERMEP. Simultaneously with the PET acquisition, brain MRI sequences will be acquired: 3D anatomical T1 and 3D T2, SWI, diffusion MRI (DTI), resting-state functional MRI, and arterial spin labeling (ASL) perfusion MRI. Patients will undergo two PET-MRI scans on two consecutive days under two pharmacological conditions: Off and On dopamine: * Day 1:\*\* The first PET-MRI session (TEPDopaOff) will be performed after a 12-hour withdrawal from usual dopaminergic treatment (Off dopamine). * Day 2:\*\* The second PET-MRI session (TEPDopaOn) will be similar to the first, except it will take place 1 hour after administration of immediate-release Levodopa
[¹¹C]raclopride binding potential (BP, unitless) measured with PET-MRI in mesocorticolimbic brain structures between participants with and without RBD, off treatment.
The primary outcome measure corresponds to the Difference in binding potential (BP) of \[¹¹C\]raclopride in the brain structures of the mesocorticolimbic network between groups with and without RBD at baseline evaluation, off treatment, derived from PET-MRI imaging in mesocorticolimbic brain structures. The measurement tool is the \[¹¹C\]raclopride PET-MRI. BP is a unitless quantitative parameter (ratio between specifically bound radioligand and non-displaceable radioligand in tissue).
Time frame: During MRI exploration (3 months after inclusion visit)
[¹¹C]raclopride binding potential (BP, unitless) measured with PET-MRI in mesocorticolimbic brain structures between participants with and without RBD following acute administration of Levodopa
Time frame: During MRI exploration (3 months after inclusion visit)
MDS-UPDRS III motor score
UPPS impulsivity scale score
Time frame: at the inclusion visit
Starkstein apathy scale score
Time frame: at inclusion visit
BDI depression score
Time frame: at inclusion visit
Ardouin Scale of Behavior in Parkinson's Disease) scores (hypodopaminergic and hyperdopaminergic items)
Time frame: at inclusion visit
Total levodopa equivalent dose and for agonists (in mg/day)
Time frame: at inclusion visit
Voxel-wise parametric statistical maps (SPM) across the whole brain comparing PET parametric images ([¹¹C]raclopride BP)
Time frame: During MRI exploration (3 months after inclusion visit)
Voxel-wise parametric statistical maps (SPM) across the whole brain comparing MRI images.
Time frame: During MRI exploration (3 months after inclusion visit)
Started May 2026 (actual). Primary completion is estimated for Jan 2028, 19 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Disruptive, Impulse Control, and Conduct Disorders →
University Hospital, Clermont-Ferrand →